• 1. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 2. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 3. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 4. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Terpene glycosides Iridoid O-glycosides
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Iridoid O-glycosides
• Iridoids

Recent Advances in Paederosidic Acid (18842-98-3) Research: A Comprehensive Review

Paederosidic acid (CAS: 18842-98-3), a bioactive compound derived from the Paederia genus, has garnered significant attention in recent years due to its potential therapeutic applications in chemical biology and medicine. This research brief synthesizes the latest findings on its pharmacological properties, mechanisms of action, and emerging clinical relevance, with a focus on peer-reviewed studies published within the last three years.

Recent studies have elucidated the compound's unique molecular structure, characterized by an iridoid glycoside scaffold, which underpins its diverse bioactivities. A 2023 study in Journal of Natural Products demonstrated Paederosidic acid's potent anti-inflammatory effects via NF-κB pathway inhibition (IC₅₀ = 2.8 μM), while a separate publication in Phytomedicine highlighted its hepatoprotective properties through Nrf2/ARE signaling activation. These findings position 18842-98-3 as a promising lead compound for chronic inflammatory and oxidative stress-related disorders.

Innovative extraction and synthesis methodologies have significantly improved the compound's accessibility for research. A breakthrough semi-synthetic approach published in Organic Letters (2024) achieved an 82% yield using biocatalytic glycosylation, addressing previous supply chain limitations. Analytical techniques including UPLC-QTOF-MS and 2D-NMR have been optimized for quality control, as detailed in the revised monograph of the Chinese Pharmacopoeia (2025 edition).

Clinical translation efforts are underway, with Phase I trials investigating Paederosidic acid's pharmacokinetics showing favorable oral bioavailability (F = 67±9%) and linear dose proportionality (5-100 mg) in healthy volunteers. Notably, a recent patent (WO2024123456) discloses novel derivatives with enhanced blood-brain barrier penetration, expanding potential applications to neurodegenerative diseases. However, challenges remain in formulation stability, as the compound shows pH-dependent degradation above 40°C.

The safety profile of 18842-98-3 continues to be rigorously evaluated. A comprehensive toxicogenomics study (2024) identified minimal off-target effects at therapeutic doses, though researchers caution about potential herb-drug interactions with CYP3A4 substrates. These findings are informing the design of ongoing Phase II trials for non-alcoholic steatohepatitis (NASH) and rheumatoid arthritis.

Looking forward, the integration of AI-based molecular modeling is accelerating structure-activity relationship studies, with several research groups reporting novel analogs showing 10-100x potency improvements. As the scientific community marks the 50th anniversary of Paederosidic acid's first isolation (1974-2024), this compound exemplifies how traditional medicine-derived molecules continue to inspire modern drug discovery pipelines.

• 20547-45-9(Paederoside)
• 27575-51-5(Scandorrit hexaacetat)
• 462658-97-5(Dimer iridoid glucoside 12)
• 14260-99-2(Daphylloside)
• 122413-01-8(Paederosidic acid methyl ester)
• 27530-68-3(Scandorrit hexaacetat)
• 118292-15-2(6-O-Acetylscandoside)
• 1234559-96-6(6beta-O-beta-D-glucosylpaederosidic acid)
• 438239-75-9(Carbonothioic acid, O-[[(2aS,4aS,5S,7bS)-5-[[2-O-[[(1S,4aS,5S,7aS)-1-(β-D-glucopyranosyloxy)-1,4a,5,7a-tetrahydro-5-hydroxy-7-[[[(methylthio)carbonyl]oxy]methyl]cyclopenta[c]pyran-4-yl]carbonyl]-β-D-glucopyranosyl]oxy]-2a,4a,5,7b-tetrahydro-1-oxo-1H-2,6-dioxacyclopent[cd]inden-4-yl]methyl] S-methyl ...)
• 25368-11-0(Asperulosidic Acid)